Knight Therapeutics Inc KHTRF

Primary Symbol: T.GUD

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Paladin Labs' Revenue Guidance (2007-2012)

<< Previous

Bullboard Posts

Next >>

Comment by curiousjon Apr 02, 2023 9:22am

90 Views

Post# 35374435

RE:Paladin Labs' Revenue Guidance (2007-2012)

gap still remains between Paladin's margins and Knight's. what's weighing on Knight is amortization is high and GM are low, they paid for GBT and license agreements have too high royalties.

Further the GM% from exelon should of delivered a lot higher especially given the price paid

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments